N otch signaling plays a critical role in the development and homeostasis of the vasculature. 1 Four mammalian Notch receptors (Notch1 through Notch4) and at least 6 Notch ligands (Delta-like [Dll]-1, Dll3, Dll4, Jagged1, Jagged2, and F3/ contactin) have been identified. Perturbation of Notch signaling is implicated in the pathogenesis of cardiovascular diseases. Vascular injury induces expression of Notch and its ligands, 2 and Notch signaling regulates postnatal vascular remodeling. 3 Vascular cells have a finite lifespan and eventually enter an irreversible growth arrest called cellular senescence. Senescence is recognized by changes in nucleation, cell morphology and strong senescence-associated neutral ␤-galactosidase (SA-␤-gal) activity. Endothelial cells (EC) in aged humans were demonstrated to have active ␤-gal activity in the aorta overlying regions of atherosclerosis, suggesting a link between endothelial senescence and vascular pathology. 4 Although diverse stimuli can induce cellular senescence, they converge on 2 major pathways, p53 and retinoblastoma protein (Rb). 5 Both pathways integrate signals that mediate cell growth, survival, and expression of genes associated with senescence (p21 and p16 INK4a ). 6 Senescence also leads to changes in vascular endothelial-barrier function, which is mediated in part by adherens junctional proteins, including vascular endothelial (VE)-cadherin and ␤-catenin. 7, 8 In addition, small G-proteins such as the GTPase and RhoA increase actomyosin contractility, which facilitates the breakdown of intercellular junctions, causing barrier dysfunction. 9 Rho family members mediate myosin light chain (MLC) phosphorylation through their effector molecules, Rho kinase/ROCK/ROK. Rho activates Rho kinase, which phosphorylates the myosin-binding subunit of myosin phosphatase, inhibiting its function. The phosphorylation state of substrates including MLC affects the permeability of EC and intact venules. Alternatively, inhibition of either RhoA or Rho kinase can reduce cell permeability induced by thrombin. 10 Our study identifies a positive link between Notch signaling and the Rho kinase pathway that regulates EC phenotype.
Methods
All experiments presented were reproduced in a minimum of 3 independent trials and analyzed statistically for significance using the Student t test or as indicated. Details are provided in the Supplemental Material, available online at http://atvb.ahajournals.org.
Constructs and Gene Expression
Gene expression adenoviral constructs were described 11 : Notch intracellular domain (NICD), dominant-negative CBF1, RhoL63, Notch target genes HRT1, and HRT2 constructs have C-terminal epitope tags. Primary human umbilical vein EC (HUVEC) from Lonza (Walkersville, MD) were cultured in complete endothelial growth medium 2 (EGM-2) with supplements in a humidified atmosphere of 5% CO 2 at 37°C.
Assays
Three dimensional tubulogenesis assays were performed as described. 12 SA-␤-gal assay (Sigma) and measurement of telomerase activity (US Biomax) were done according to the manufacturers' instructions. Macromolecule permeability of Rhodamine B isothiocyanate (RITC)-dextran across monolayers 13 and Rac/Rho activity were quantified as described. 14 
Quantitative Reverse Transcription-Polymerase Chain Reaction
Total RNA extracted using Tri-Reagent (Sigma) was DNAase-1 treated (Promega), and quantitative reverse transcription-polymerase chain reaction was performed as described. 11
Immunoblotting
Cell lysates were prepared, 11 and proteins were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes (Bio-Rad), immunoblotted, and visualized by ECL (Amersham Biosciences). The following antibodies were detected: V5 (Invitrogen); ␤-actin, HA, and FLAG (Sigma); and p53, p27, p21, p15, cyclin D1, cyclin D3, and Rb (Cell Signaling Technology).
MBS and MLC Phosphorylation
Transfected cells were maintained in EGM-2 for 5 to 6 days, and some were treated with Y27632 (20 mol/L) or ML9 HCl (10 mol/ L). Cells were rinsed twice with cold PBS, fixed with 10 mmol/L dithiothreitol and 10% trichloroacetic acid, scraped, centrifuged at 4°C, washed 3 times in cold acetone with 2 mmol/L dithiothreitol, and solubilized by sonication in sample buffer. The protein was resolved followed by immunoblotting with phospho-specific antibodies against myosin binding subunit (MBS) Thr853 and myocin light chain (MLC) Thr18/Ser19.
Results

Late-Passage EC Have Elevated Notch Signaling Components
Expression analysis of passage 31 EC compared with rapidly cycling early-passage cells (passage 4) showed significant in-creases in transcripts of all Notch receptors; Notch ligands Dll1, Dll4, and Jagged1; and the Notch target genes HRT1 and HRT2 ( Figure 1A ). The immunoblot showed corresponding increases in Notch1 over serial passage, with moderate levels at passage 6 and significant increases by passage 23 ( Figure 1B ).
Immobilized Dll4 Ligand Activation of Notch Signaling Induces Senescence Phenotype
When stimulated by immobilized recombinant human Dll4 (rhDll4) ligand, EC have increased expression of Notch receptors and Notch targets HRT1, HRT2, and HES1 ( Figure 1C ). This is associated with decreased cell number and proliferation ( Figure 1D ). Notch activation by rhDll4 also led to an increase in SA-␤-gal activity indicative of replicative senescence after 72 hours, comparable to passage 31 naturally senescent EC ( Figure  1E ). Endothelial cultures at early passage had few SA-␤-galpositive cells, but they stained highly (70% to 80%) at later passages when they reached replicative senescence. As Dll4 ligands are likely to activate multiple Notch receptors, we tested activation of Notch signaling using expression of constitutively active NICD receptors.
Notch Activation Suppresses EC Cycle Progression and Angiogenic Phenotype and Induces Cellular Senescence
Adenoviral constructs encoding the intracellular domains of Notch1, Notch2, and Notch4 were characterized previously, 11 and expression of NICD or HRT in EC was confirmed by immunostaining (Supplemental Figure IA) and immunoblot (Supplemental Figure IB) . Under our conditions, Ϸ90% of the population expressed the gene of interest on day 3 after transduction. As the senescence phenotype suggests a change in growth, we analyzed cell proliferation. Activation with NICD A, Quantitative reverse transcriptionpolymerase chain reaction for serially passaged EC (passages 4 to 31) showing transcripts for Notch1 (N1), Notch2 (N2), Notch3 (N3), Notch4 (N4), Dll1, Dll4, Jagged1 (Jag1), HRT1 (H1), HRT2 (H2), and HES1, expressed as fold increase in passage 31 cells compared with passage 4 cells. B, Immunoblot of EC at passages 6, 16, and 23 for Notch1 receptor and quantification. C, EC were activated using rhDll4, and quantitative reverse transcription-polymerase chain reaction was performed for Notch1-4, HRT1 (H1), and HRT2 (H2). D, rhDll4-activated EC were quantified for cell number and 5-bromo-2Ј-deoxyuridine (BrdU) incorporation. E, SA-␤-gal staining was compared in early-or late-passage EC and early-passage EC activated by rhDll4 ligand. Scale barϭ50 m.
inhibited EC cycle progression with decreased growth rates lower than control green fluorescent protein (GFP)-expressing cells. Notch-activated cells had an increase in percentage of cells in G 1 and a significant decrease of cells in S phase. However, cells overexpressing HRT1 or HRT2 did not show altered cell proliferation as determined by 5-bromo-2Ј-deoxyuridine (BrdU) incorporation, suggesting that HRT activation is not the causal step in regulating cell cycle progression ( Figure 2A ).
As Notch signaling suppressed cell growth, we tested other phenotypic measures of EC function, including sprouting and migration. Using an in vitro gel sprouting assay, 15 we found that active Notch signaling blocked spontaneous endothelial sprout formation on gelatin-coated beads (Supplemental Figure IIA). Activation of Notch significantly inhibited the movement of EC into the denuded area in a scratch assay (Supplemental Figure IIB) . Cell migration was inhibited by 70% to 80% compared with controls. However, no difference in cell attachment was observed.
Notch-activated EC show senescence characteristics with enlarged, flattened cell morphology, increased granularity, and vacuolization. On trypsinization and replating, the cells did not proliferate, indicating that most cells had exited the cell cycle. We analyzed telomerase activity using the telomeric repeat amplification protocol assay because in EC, senescence is a consequence of progressive dysfunction of telomerase. Telomerase activity was sup-pressed in Notch-activated EC compared with control EC ( Figure 2B ). In addition, SA-␤-gal staining showed that cells with activated Notch signaling had 70% to 75% SA-␤-gal-positive cells, whereas GFP controls had fewer than 20% ( Figure 2C to 2E). This NICD-induced phenotype is comparable to late-passage EC (passage 31) at replicative senescence and early-passage cells activated by rhDll4 ligand ( Figure 1E ).
In Vivo Notch1 Activation Inhibits Aortic Ring Growth and Induces Senescence
Using our previously characterized mouse model of Notch activation (Notch1 intracellular domain [N1ICD]), 12 we activated Notch signaling in vivo in EC using tamoxifeninducible Tie2Cre and analyzed vascular outgrowth from explanted aortic rings. Formation of endothelial tubules from explanted aortic rings starts after Ϸ4 days, forming a branching vascular network after 10 days ( Figure 2F ). In aortae with N1ICD expressed in endothelium, there was initiation of short tubular outgrowths. However, they failed to branch or elongate to generate a vascular network. The N1ICD aortic outgrowth showed characteristics of senescence, with elevated SA-␤-gal staining. In vivo, increased SA-␤-gal activity was seen in the endothelium of the dorsal aorta and coronary arteries, particularly in regions surrounding branch points with activated Notch signaling. Shown is sprouting from control and Notch-activated mouse aortic ring. Aortic rings were cultured in Matrigel in EGM-2, and after 5 days, control rings showed numerous sprouts and tubular network formation at periphery. Notch-activated rings had fair number of sprouts but failed to form a tubular network. SA-␤gal staining was the same, indicating increased SA-␤-gal activity in Notch-activated aorta; inset shows higher magnification of a ␤-gal-stained Notch-activated EC and SA-␤-gal activity in the endothelial layer of Notch-activated mouse dorsal aorta.
Mitogen-Activated Protein Kinase Mediated p53 and p16 Activation in Notch-Induced Senescence
We tested signaling mediators downstream of Notch activation. Immunoblot analysis for active mitogen-activated protein kinase (MAPK) in EC with activated Notch signaling showed increased phosphorylation of extracellular signal regulated kinase (ERK) and AKT ( Figure 3A ). Notchinduced ERK activation requires mitogen activated protein kinase kinase (MEK) activity, because the MEK1 inhibitor U0126 prevented Notch-induced phosphorylation (data not shown). It is known that the funneling of cellular signals to p53 and pRb determines the onset of senescence. 16 We found significant increase (2.5 fold) of p53 in Notch-overexpressing cells ( Figure 3B ), late-passage nontransduced cells ( Figure  3D ), and p53 phosphorylation ( Figure 3E ) in Notch activated cells. When treated with the inhibitor U0126, p53 levels decreased correspondingly (Supplemental Figure III) . In addition, Notch activation led to increased transcript and protein of the cell cycle regulator p21 Cip1/Waf1 in both Notch-activated cells and later-passage nontransduced cells ( Figure 3B to 3D). This is consistent with cell cycle arrest in late G 1 phase, which is regulated by the Cdk inhibitor p21 Cip1/Waf1 , a transcriptional target of the p53 tumor suppressor. 17 Because induction of the Cdk inhibitor p16 INK4a is associated with the onset and maintenance of senescence, 18 we performed immunostaining 72 hours postinfection with either the control GFP or NICD. NICD-activated cells showed a large percentage of p16-positive cells compared with controls ( Figure 3E ). Collaboration of p16 INK4a and p21 Cip1/Waf1 prevents phosphorylation of Rb, leading to a stable G 1 arrest in senescent cells. 19 Similarly, our results show moderately increased Rb in Notch-activated EC ( Figure 3B ). Low cyclin D1-associated kinase activity in senescent EC results from a diminution of cyclin D1-Cdk 4/6 complexes owing to p16 accumulation, as proposed earlier. 20 Although there was no difference in cyclin D1 levels, there was a more than 2-fold increase in cyclin D3 in Notch activated cells ( Figure 3B) , showing regulation of multiple pathways by Notch activation. In addition, rhDll4 ligand-activated cells showed increases in p21 and p53, as determined by immunoblot (data not shown). 
Notch Signaling Induces Hyperpermeability Associated With Disruption of Cell Junctions
Because senescence also leads to a change in EC function, 21 we measured endothelial monolayer integrity using rhodamine B isothiocyanate (RITC)-dextran permeability. Notch activation led to a significant increase in transendothelial dextran diffusion similar to thrombin, the positive control ( Figure 4A ). Cells were fixed and stained for F-actin (phalloidin) and adherens junction proteins. Following Notch activation, EC showed dramatic rearrangement and restructuring of the F-actin network. The monolayer no longer exhibited cobblestone morphology; cells instead appeared spindle shaped, with evident intercellular gaps ( Figure 4B to 4E). Furthermore, Notch activation induced dissolution of the dense peripheral actin band, with the fine reticular cortical F-actin network replaced by thick stress fibers that were arranged parallel to the spindle axis of the cells. Furthermore, we monitored the subcellular distribution and expression of ␤-catenin ( Figure 4F ). Whereas control cells have a robust, pericellular junctional localization of ␤-catenin, following Notch activation, there was a profound decrease in ␤-catenin expression at regions of cell-cell junctions, and there were large intercellular spaces. To visualize integrity of adherens junctions, endothelial monolayers were stained for VEcadherin, which are normally localized to regions of cell-cell contact ( Figure 4G ). In Notch-activated cells, VE-cadherin was diminished and even lost from most cell-cell contact areas. Total cellular protein levels of VE-cadherin and ␤-catenin by immunoblot ( Figure 4H ) showed up to 50% reduction in cells with active Notch signaling.
Involvement of MLC Phosphorylation in Notch-Induced Actin Cytoskeleton Reorganization and Hyperpermeability
Activation of Notch signaling in EC leads to significant enhancement of MLC phosphorylation on Thr18 and Ser19 ( Figure 5A ). The increase in MLC phosphorylation correlated well with increased permeability. We next determined the Rho kinase activity, phosphorylation at T696 of myosin phosphate targeting subunit 1 (MYPT-1) by Rho kinase, previously reported to inactivate the myosin phosphatase and serve as a surrogate marker for Rho kinase activity. 22 Expression of pMYPT1 was detected by immunoblot, demonstrating increased phosphorylation corresponding to active Notch signaling ( Figure 5A ).
Rho Kinase Mediates Notch-Induced Hyperpermeability
Because Rho kinase activated by Rho-GTP plays a prominent role in the regulation of endothelial barrier function, 23 we assayed RhoA and Rac activity based on binding of activated RhoA (RhoA-GTP) to the Rho effector Rhotekin (glutathione S-transferase-Rhotekin) protein, 10 reflected in the pull-down fraction. In control cells, basal levels of RhoA-GTP were detected, which were elevated in cells with active Notch signaling ( Figure 5B ). However, the overall amount of RhoA did not change. In contrast, the activity of Rac, measured by use of a glutathione S-transferase-Pak fusion protein was not regulated by Notch activation. With evidence supporting Notch activation of RhoA, we next asked whether Notch and RhoA act synergistically. To test this, we analyzed Notch and constitutively active RhoL63 on Notch signaling target genes HRT and HES expression, which are induced by Notch signaling. 11 HRT and HES were significantly upregulated by Notch, as expected ( Figure 5C ). Interestingly, constitutively active RhoA alone had minimal effect on Notch target genes ( Figure 5D ) but strongly upregulated HRT and HES in the presence of N1ICD ( Figure 5E ). Ectopic expression of a dominant-negative CBF1/RBP-j attenuated the effect of NICD as well as the synergistic effect of N1ICD and active RhoL63 ( Figure 5F ). Because there was robust activation of Notch signaling in the presence of RhoL63, we tested the effect of Rho kinase inhibitor (Y27632) on Notch signaling. Incubation of Notch-activated EC with Y27632 significantly reduced HRT and HES expression ( Figure 5G ). In addition, there was significant reduction in HRT and HES expression during Notch and RhoL63 activation in the presence of the Rho inhibitor ( Figure 5H ).
Inhibition of Rho Kinase Reverses Hyperpermeability and Senescence by Inhibiting Notch Signaling
We used the Rho kinase inhibitor Y27632 (10 mol/L) to determine whether Rho kinase mediates the increase in MLC phosphorylation. Inhibition of Rho kinase significantly reduced MLC and MYPT1 phosphorylation under both basal and Notchactivated conditions ( Figure 6A ). Similar studies were conducted with the MLC kinase (MLCK) inhibitor ML-9HCl, which did not affect Notch induction of MLC or MYPT1. Because the Rho kinase inhibitor blocked MLC and MYPT1 phosphorylation, we tested whether this led to functional change in cell permeability. Incubation of the endothelial monolayer with Y27632 significantly attenuated the endothelial permeability induced by Notch signaling ( Figure 6B ). Furthermore, the changes in F-actin morphology and ␤-catenin induced by Notch activation were also blocked by Rho kinase inhibition ( Figure  6C ). Similar to the phosphorylation and permeability results, this was selective, because treatment with Y27632 but not ML-9HCl was able to reverse the Notch-induced changes in cytoskeletal morphology and barrier function.
Discussion
Notch signaling mediates cell fate decisions and differentiation 24 and vascular development. 12 Previous studies have shown that Notch signaling inhibits EC growth. 25 Although there is evidence that the Dll ligands contribute to growth arrest, 26 this has not been well characterized. Our studies show an association of increased Notch ligand and receptor expression during senescence in human cells in vitro. Increased SA-␤-gal staining in Notch-activated dorsal aorta and aortic ring cultures showed a parallel activity in vivo. This is of interest as a potential link between endothelial senescence and vascular pathology in vivo, such as in human atherosclerotic lesions that have been shown to be areas of endothelial senescence. 4 In this report, we present evidence to show that the mitogen-activated protein kinase-ERK pathway is associated with Notch-induced senescence like growth inhibition in human EC. Studies indicate that the RAS/RAF/ERK pathway mediated p21 cip and p27 kip regulation is responsible for cell cycle arrest. 27, 28 Our results are consistent with the previous finding that Notch activation increases transcriptional activity of p53, resulting in upregulation of p21 mediated by ERK in cancer cells. 29 In keeping with its function as a Cdk inhibitor, p21 is highly expressed in senescent cells and inhibits DNA synthesis. Moreover, overexpression of p21 can result in premature senescence. Although senescence strongly correlates with accumulation of p53/p21, 30 this is probably not the only factor involved in Notch-induce senescence. In human EC, induction of p16 INK4a is also associated with senescence. 28 Our results show a robust increase in p16 INK4a and cyclin D3 and decreased cyclin D1 correlating with increased binding of p16 INK4a , resulting in decreased cyclin D1 and pRb in senescent cells. Accumulation of p16/p21 results in inactivation of all G 1 cyclin-Cdks, such that Rb fails to be phosphorylated, E2F transcription factors are not released, late-G 1 genes necessary for DNA synthesis are not expressed, and the cells become irreversibly arrested in G 1 phase. 31 Because p21 and p16 have very different agerelated patterns of accumulation, we propose that senescence in human EC comprises 2 events: first, the progressive age-dependent accumulation of p21 suggests that it occurs as a consequence of replication-related processes, 32 and second, a program of differentiation is modified that involves the accumulation of p16 INK4a , as well as changes in the morphology, size, and functional attributes, including barrier permeability of the cells.
Our study also investigates senescence-associated changes in EC permeability. Recent evidence suggests that lung permeability increases during a period of terminal senescence in AKR/J mice. 21 Here we demonstrate a novel Notch-associated Rhodependent reorganization of actomyosin stress fibers and disruption of adherence junctions, which lead to loss of barrier integrity along with the senescence phenotype. Dissociation of the VEcadherin-␤-catenin complex from the cytoskeleton causes endothelial barrier dysfunction. 33 The disorganization appears to be mediated by ␤-catenin, which forms a structural link with VEcadherin to stabilize endothelial monolayers. Consistent with the importance of cell junctional integrity, we found that Notch activation led to decreases in overall cellular VE-cadherin and ␤-catenin and loss of their localization to regions of cell contact.
We have clearly demonstrated that RhoA is activated by Notch in EC. Under basal conditions, RhoA is present at low levels, suggesting that RhoA, unless activated, has little or no effect on basal barrier integrity. Previous studies indirectly suggest the involvement of RhoA in endothelial permeability largely based on use of C3 transferase, or toxin B, which inhibits RhoA, Rac, and Cdc42. Inactivation of RhoA, Rac, Figure 6 . The Rho inhibitor Y27632 but not ML9-HCl prevents active Notchinduced MLC phosphorylation. A, Notchactivated EC were treated with Y27632 (10 mol/L) or ML-9HCl (20 mol/L), followed by measurement of MLC phosphorylation. N indicates Notch. B, Rho kinase activity mediates cytoskeletal changes and Notch-induced permeability. Monolayer permeability assays were performed to test the effects of Y27632 (20 mol/L) or ML-9HCl (10 mol/L) on Notch activation in EC. C, Immunostaining using phalloidin to detect F-actin (upper panels) or ␤-catenin (lower panels) in control (GFP), Notch-activated cells, or Notch-activated cells in the presence of Y27632 (20 mol/L). Scale barϭ50 m. D, Model of the mechanism of action of RhoA and Notch activation resulting in EC senescence. MAPK indicates mitogen-activated protein kinase. and Cdc42 disrupts the endothelial barrier. 10 MLC phosphorylation plays a pivotal role in initiating actomyosin interaction and in the development of barrier dysfunction. Here, we show that Rho kinase contributes to MLC phosphorylation in EC. This is comparable to its activity in smooth muscle cells and platelets, 34 where Rho kinase is involved in MLC phosphorylation by inhibiting the myosin phosphatase. Our results suggest a similar mechanism, as activation of Notch inhibits myosin phosphatase. Therefore, our data point to an important role for RhoA and Rho kinase in the regulation of endothelial permeability downstream of Notch signaling and link these pathways to endothelial senescence ( Figure 6D ).
